The Relationship Of Hormonal Level And Correlational Study Of Pre-therapy And Post-treatment With Ais For Breast Cancer In Postmenopausal Women

Background and ObjectiveThe incidence of breast cancer increased year by year in the past decades. Due to it is taken more seriously, the mortality rate of breast cancer decreased obviously in western developed country. Although the pathogenesis of breast cancer is not clear now, it is confirmed that the occurrence and progress of breast cancer are closely associated with irregular sex hormone level by large number of clinical and experimental studies abroad. With rapid development of the human productivity in China, the women’s estrogen levels have been increased by the kinds of additives in food&drug, which have the function similar as sex hormone, and the unbalanced food intake etc. And for the women in the postmenopausal, the estrogen mainly comes from the biotransformation of androgen from adrenal glands due to ovarian failure and estrogen production reduced. The estrogen is produced in the biotransformation process from androstenedione to estradiol under catalysis of aromatase from surrounding tissue which is a rate-limiting enzyme. Aromatase inhibitors (AIS) can disable the rate-limiting role of aromatase which stops the biotransformation to estrogen and decreases the estrogen levels effectively. Thus, AIs inhibits the growth of tumor cells under the action of estrogen. There is a large number of reports comparing the serum levels of sex hormone ER(+)&ER(-) for post-menopausal breast cancer both at home and abroad which mostly show no direct relevance with each other. But there is limited report comparing the serum levels of sex hormone of ER(+)&ER(-) for benign breast lesions. Considerable abroad researches via system group method show taking AIs will decrease the estrogen levels effectively in AIs surveillance, but limited dynamic surveillance was taken in China. In this paper, we attempt to start preliminary discussion on the relationship of ER(+)/ER(-) and hormonal levels for benign breast lesions, and correlational study of pre-therapy and post-treatment with AIs for breast cancer in postmenopausal.Material and MethodsSelect the cases of postmenopausal women which for treatment from January2010to November2012in the department of breast surgery Second Affiliated Hospital of Zhengzhou University, of which31cases of patients with breast cancer ER (+)、16cases of breast cancer ER (-) and47cases of benign breast lesions(control group). Select37cases of breast cancer takin the AIS continuously more than one year in the same period. Aged55to82years, with a median age of64years. These patients were detected the levels of sex hormones by radioimrnunoassay、 cleared pathological diagnosis and determined the ER status by immunohistochemistry which patients with breast cancer. All of the data using SPSS18.0to organize and analyze. Using the form of the mean±standard express the measured data. Using one-way ANOVA compare three groups. Using SNK-q test compare two groups; The data which in the period of before and after treatment were compared by paired-samples T test. Compare serum levels of sex hormone with E2、 T、 P in the group of ER (+) and the group of ER (-) postmenopausal breast cancer and the control group. Compare serum levels of sex hormone E2、 T and P in the postmenopausal breast cancer which taking AIs before and after. Follow-up time of12-49months, with a median follow-up time of28months.Results 31samples of ER(+) and16samples of ER(-) in postmenopausal breast cancer compared with16samples of postmenopausal breast benign lesions respectively in hormonal levels, the sample of ER(+) and ER(-) both higher than the controls group in estradiol and testosterone. Compared with the hormonal levels of ER(+) and ER(-) has no difference statistically in postmenopausal breast cancer with ER(+). There is no statistical difference between the three groups in progesterone(P=0.392>0.05). Compared with the hormonal levels before and after takin AIs, estradiol dropped sharper than before(P<0.05), but testosterone increased(P<0.05), and there is no obvious difference statistically on progesterone (P=0.799)。ConclusionRegardless of ER status, postmenopausal breast cancer compared with postmenopausal benign breast disease in estradiol、 testosterone showed a higher level.Suggesting the occurrence and development of breast cancer may be associated with sex hormone levels. After taking AIs, the patients of postmenopausal breast cancer ER (+) estradiol reduced and testosterone elevated significantly,and no significant change in progesterone.